智通财经APP讯,再鼎医药(09688)发布2025年中期业绩,该集团取得总收入2.16亿美元,同比增加15.35%;亏损净额8916.5万美元,同比减少33.33%;每股亏损0.08美元。
产品收入净额增加2750万美元(或15%)至2.15亿美元,主要由于卫伟迦的销售额受疗程延长及市场渗透率提升的推动而增长、纽再乐的销售额受市场覆盖范围及渗透率提升的推动而增长及自2024年第四季度起上市的鼎优乐的销售额增长。
研发开支减少490万美元(或4%)至1.11亿美元,主要由于持续的资源优化及效率提升令人员和临床试验成本减少,部分被许可费增加所抵销。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.